8-K

================================================================================
                                  UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                              Washington, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT

                       Pursuant to Section 13 or 15(d) of

                       The Securities Exchange Act of 1934

                Date of Report (Date of earliest event reported)

                                January 27, 2005

                          MIRAVANT MEDICAL TECHNOLOGIES

             (Exact name of registrant as specified in its charter)

            Delaware                          0-2554            77-0222872
            --------                          ------            ----------
 (State or other jurisdiction of    (Commission File Number)  (IRS Employer
         incorporation)                                      Identification No.)

                                336 Bollay Drive

                             Santa Barbara, CA 93117

          (Address of principal executive offices, including zip code)

                                 (805) 685-9880

              (Registrant's telephone number, including area code)

          (Former name or former address, if changed since last report)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):

[    ] Written communications  pursuant to Rule 425 under the Securities Act (17
     CFR 230.425)


[    ]  Soliciting  material  pursuant to Rule 14a-12 under the Exchange Act (17
     CFR 240.14a-12)


[    ]  Pre-commencement  communications  pursuant  to Rule  14d-2(b)  under the
     Exchange Act (17 CFR 240.14d-2(b))

[    ]  Pre-commencement  communications  pursuant  to Rule  13e-4(c)  under the
     Exchange Act (17 CFR 240.13e-4(c))

================================================================================




Item 5.02 Departure of Directors or Principal  Officers;  Election of Directors;
Appointment of Principal Officers.

(d)  On  January  27,  2005,   the  board  of  directors  of  Miravant   Medical
Technologies,  or Miravant,  appointed Robert J. Sutcliffe and Michael Khoury as
new  directors  to the  board.  The board has  determined  that each of  Messrs.
Sutcliffe and Khoury are  independent  of Miravant and its  management.  Messrs.
Sutcliffe and Khoury have both been named to the board's Audit and  Compensation
Committees.

A copy of the press  release  issued on January 31, 2005 by Miravant  announcing
the appointments of Messrs. Sutcliffe and Khoury to the board is attached hereto
and incorporated by reference herein.

Item 9.01.  Financial Statements and Exhibits.

 (c)  Exhibits.

Exhibit No.    Description


99.1           Press Release issued by the Company dated Janaury 31, 2005.









                                   SIGNATURES

          Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                          Miravant Medical Technologies

                             By:/s/ John M. Philpott
                                ------------------------------------
                                    John M. Philpott
                                    Chief Financial Officer

Date:  January 31, 2005







                                  EXHIBIT INDEX

Exhibit No.    Description

99.1           Press Release issued by the Company dated January 31, 2005.

EX-99

                                                          FOR IMMEDIATE RELEASE

Contact:  Tom Herrick
          Investor Relations
          (805) 685-9880

                       ROBERT SUTCLIFFE AND MICHAEL KHOURY
                        JOIN MIRAVANT BOARD OF DIRECTORS

SANTA BARBARA,  Calif., January 31, 2005 - Miravant Medical Technologies (OTCBB:
MRVT),  a  pharmaceutical  development  company  specializing  in  PhotoPoint(R)
photodynamic therapy (PDT), announced today the elections of Robert J. Sutcliffe
and Michael Khoury to its board of directors.

Robert Sutcliffe, a venture lawyer and business advisor based in Los Angeles, is
the managing  director of Craftsman Capital Advisors LLC, and specializes in the
representation  of entrepreneurs  and venture investors in a range of industries
including  biotechnology.  A graduate of UCLA and  Harvard  Law  School,  he was
partner  and group  chairman in a  corporate  law firm until  1989,  focusing on
venture   capital,   corporations   and  securities.   He  then  served  as  the
congressional  chief of staff to the Honorable  Christopher  Cox of  California.
Subsequently he was director,  chief  operating  officer and general counsel for
International  Medication Systems Limited, a manufacturer of pharmaceuticals and
drug delivery devices. In 1995 he co-founded Digital Gene Technologies,  Inc., a
genomics-based  drug  discovery  and  development  company,  where he  served as
director,  president and chief executive  officer.  He is a founding director of
Neurome,   Inc.,  a  discovery-stage   biotechnology   company  specializing  in
therapeutics for neurodegenerative diseases.

Michael  Khoury,  a  Los  Angeles-based  independent  consultant  to  a  private
investment group, holds an MFA from New York University  (Fulbright Scholar) and
an MBA from the UCLA Anderson Graduate School of Management.  A certified public
accountant,  he was a senior  manger with  Deloitte & Touch until 1993.  He then
served as  president  and chief  executive  officer of First  National  Mortgage
Exchange,  Inc.,  which he  rebuilt  and sold in 1998 to  FirstPlus,  a  leading
NYSE-traded  mortgage bank. He  subsequently  served as senior vice president of
IMC Mortgage,  a consumer  finance  company.  In 1999 he became chief  executive
officer of InterScore, a consulting firm specializing in E-commerce engineering,
successfully selling the firm in 2000 to Ballantyne, an information technologies
consulting and staffing  company.  He currently serves as director on the boards
of Neurome, Inc. and SourcingLink, Inc.

Gary S.  Kledzik,  PhD,  chairman and chief  executive  officer,  stated,  "I am
extremely  pleased  with the  additions  of Bob  Sutcliffe  and Mike  Khoury  to
Miravant's board of directors,  both experienced  entrepreneurs  with impressive
business and financial strengths."

About Miravant

Miravant Medical  Technologies  specializes in  pharmaceuticals  and devices for
photoselective medicine,  developing its proprietary PhotoPoint(R)  photodynamic
therapy  (PDT)  for  large  potential  markets  in  ophthalmology,  dermatology,
cardiovascular   disease  and  oncology.   PhotoPoint  PDT  uses   photoreactive
(light-activated)  drugs to selectively target diseased cells and blood vessels.
The Company's lead drug, Photrex(TM),  is in clinical development as a treatment
for wet age-related  macular  degeneration and has received an approvable letter
from the U.S. Food and Drug Administration.  Miravant's  cardiovascular  program
focuses on life-threatening  coronary artery diseases, with PhotoPoint MV0633 in
advanced  preclinical testing for  atherosclerosis,  atherosclerotic  vulnerable
plaque and restenosis.

                                                      # # #